Ľubica Procházková
Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system with various clinical presentations. The main aim of treatment of the relapsing-remitting form of multiple sclerosis (RR MS) is to decrease the disease activity, i.e. to reduce the number of attacks, to slow the progression of disability adversely affecting patients’ quality of life. Apart from interferon beta, which has been used in treatment since 1993, also glatiramer acetate has been available for patients with the relapsing-remitting (RR) form of multiple sclerosis since l996. Glatiramer acetate, an immuno-modulation product based upon amino acid structure of myelin basic protein (MBP), represents one of the first possibilities of antigen-specific therapy for multiple sclerosis. Since April 1st 2006 it has been available also for patients in the Slovak Republic as a first-choice drug for RR MS.